Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-16

Study Completion Date

2019-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days in 3 consecutive weeks) oral administration of combination Dasatinib (100 mg/d) + Quercetin (1250 mg/d) will be safe and well tolerated in patients with IPF. Treatment with D+Q will result in reduced abundance of pro-inflammatory cells within subjects over baseline. Finally, the reduction in biomarkers of cellular pro-inflammatory state will be related to no change in functional and patient reported outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01529853

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE1/PHASE2

Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging

NCT03069989

Idiopathic Pulmonary Fibrosis

TERMINATED PHASE1

Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis

NCT02345070

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE2

A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01254409

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE1

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

NCT03422068

Idiopathic Pulmonary Fibrosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis (IPF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Some patients will be randomized either to placebo or study drug and other patients will go into open label.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dasatinib + Quercetin

Group Type EXPERIMENTAL

Dasatinib + Quercetin

Intervention Type DRUG

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dasatinib + Quercetin

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men between ages 50 and above, at the time of signing the informed consent.
2. Post-menopausal women ages 50 and above, at the time of signing the informed consent. Note: Postmenopausal is defined as 12 months of spontaneous amenorrhea determined by self-report.
3. A clinical diagnosis of IPF and characteristic chest HRCT scan (determined by panel of pulmonary radiologists) OR biopsy showing usual interstitial pneumonia (UIP).
4. Body Mass Index (BMI) within the range 19 - 39.9 kg/ m2 (inclusive), where BMI = (weight in kg) / (height in meters)2 .
5. Subjects participating in an exercise program must be willing to maintain their current activity level for the duration of the study period.
6. Patients on stable therapy with nintedanib (Ofev) or pirfenidone (Esbriet) over the past 3 months.ORPatients not taking nintedanib (Ofev) or pirfenidone (Esbriet) may be enrolled if they have previously not tolerated one of those medications or if those medications have not yet been prescribed or used by the patient.
7. Giving signed informed consent.
8. No plans to travel over the next 6 weeks.

Exclusion Criteria

1. More than two moderate/severe IPF exacerbations within the past year Exacerbation is defined as worsening of two or more of the following major symptoms: dyspnea, sputum volume, sputum purulence OR worsening of any one major symptom together with at least one of the following additional symptoms: sore throat, colds (nasal discharge and/or nasal congestion), fever \> 37.5 ° C without any explained cause, increased cough, increase wheeze.

A moderate exacerbation is defined as an event that is associated with a new prescription for antibiotics and/or oral steroids. A severe exacerbation is defined as an event that is associated with hospitalization or emergency room visit.
2. Any moderate/severe IPF exacerbation within the past 4 weeks.
3. History of a lung transplant.
4. Use of anti-arrhythmic medications known to cause QTc prolongation.
5. Pulmonary hypertension or cor pulmonale confirmed by echocardiography or heart catheterization.
6. Myocardial infarction, angina, hospitalization for cardiac aetiology, stroke or transient ischemic attack in the past 6 months.
7. Chronic heart failure.
8. Neurologic, musculoskeletal, or other condition that in the opinion of the study physician limits subject's ability to complete study physical assessments.
9. Uncontrolled diabetes (HbA1c \> 8% and fasting glucose \>200 mg/dL or the current use of insulin).
10. Subjects with values outside the specified ranges for the following Key Clinical Laboratory Tests must be excluded from the study:

Renal function: Glomerular Filtration Rate (GFR) \<30 (mL/min/1.73 m2) using formulae provided in the Study Reference Manual (SRM). Note: Subjects receiving dialysis are excluded from this study.

ALT \>2xULN and bilirubin \>1.5xULN (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
11. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
12. QTcB or QTcF \> 450 msec or QTc \> 480 msec in subjects with Bundle Branch Block based on a single ECG.
13. Subjects with a history of malignancy that is not in complete remission for at least 2 years or 1 year for non-melanoma skin carcinoma.
14. The subject has participated in a clinical trial and has received an investigational product within the following time period prior to participation in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
15. History of drug or alcohol abuse within 5 years prior to randomization.
16. Use of Coumadin or other anti-platelet or anti-coagulant medication. The use of aspirin is permitted.
17. Current use of quinolone antibiotics.
18. Low CBC.
19. Cognitive Impairment (MoCA score less than 21)
20. Other medical or behavioral factors that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No